A Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Brief description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Transthyretin-Mediated Amyloid Polyneuropathy,neuropathy
-
Age: Between 18 Years - 82 Years
-
Gender: All
Male or Female Age 18-82 a. Stage 1 or Stage 2 according to the Familial Amyloid Polyneuropathy (FAP) or Coutinho Stage b. Documented genetic mutation in the TTR gene c. Symptoms and signs consistent with neuropathy associated with, transthyretin.
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting